NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

VRTX

Vertex Pharmaceuticals, Inc

Jul 03 • 04:00PM ET

459.62

Dollar change +2.59
Percentage change 0.57	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB GILD AMGN REGN MRNA INCY ALNY NBIX EXEL

| Held by: VTI VOO QQQ SPY IVV VUG XLV IWF IBB QQQM

Scroll to Statements

Index	NDX, S&P 500	P/E	-	EPS (ttm)	-3.92	Insider Own	0.31%	Shs Outstand	256.97M	Perf Week	3.66%
Market Cap	118.03B	Forward P/E	22.10	EPS next Y	20.79	Insider Trans	-4.74%	Shs Float	256.02M	Perf Month	2.94%
Enterprise Value	113.47B	PEG	-	EPS next Q	4.28	Inst Own	94.73%	Short Float	1.58%	Perf Quarter	-4.94%
Income	-988.90M	P/S	10.69	EPS this Y	4183.00%	Inst Trans	6.88%	Short Ratio	2.35	Perf Half Y	15.09%
Sales	11.04B	P/B	7.16	EPS next Y	15.60%	ROA	-4.23%	Short Interest	4.03M	Perf YTD	14.13%
Book/sh	64.20	P/C	19.00	EPS next 5Y	-	ROE	-5.64%	52W High	519.88 -11.59%	Perf Year	-2.47%
Cash/sh	24.19	P/FCF	-	EPS past 3/5Y	- -	ROIC	-5.45%	52W Low	377.85 21.64%	Perf 3Y	66.43%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	13.04% 21.61%	Gross Margin	85.96%	Volatility	1.85% 2.02%	Perf 5Y	60.63%
Dividend TTM	-	EV/Sales	10.27	EPS Y/Y TTM	-124.45%	Oper. Margin	-2.99%	ATR (14)	9.43	Perf 10Y	258.10%
Dividend Ex-Date	-	Quick Ratio	2.29	Sales Y/Y TTM	8.55%	Profit Margin	-8.95%	RSI (14)	57.62	Recom	2.06
Dividend Gr. 3/5Y	- -	Current Ratio	2.65	EPS Q/Q	-40.86%	SMA20	2.36%	Beta	0.44	Target Price	507.67
Payout	-	Debt/Eq	0.10	Sales Q/Q	2.19%	SMA50	1.30%	Rel Volume	0.44	Prev Close	457.03
Employees	6100	LT Debt/Eq	0.10	Earnings	May 05 AMC	SMA200	-0.87%	Avg Volume	1.72M	Price	459.62
IPO	Jul 24, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	-4.37% -3.20%	Trades		Volume	763,957	Change	0.57%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-06-25	Downgrade	Leerink Partners	Outperform → Market Perform	$503
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$535
Feb-12-25	Upgrade	Canaccord Genuity	Sell → Hold	$408 → $424
Feb-11-25	Upgrade	Canaccord Genuity	Sell → Hold
Jan-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$460
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$600 → $535
Dec-19-24	Downgrade	Oppenheimer	Outperform → Perform
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$500 → $550
Nov-14-24	Initiated	Citigroup	Buy	$575
Oct-16-24	Initiated	Scotiabank	Sector Perform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-05-24	Downgrade	Barclays	Overweight → Equal Weight	$472 → $509
Jun-27-24	Initiated	Redburn Atlantic	Buy	$545
Apr-11-24	Upgrade	Evercore ISI	In-line → Outperform	$438
Feb-15-24	Initiated	Wolfe Research	Outperform	$515
Feb-06-24	Downgrade	Evercore ISI	Outperform → In-line	$436 → $438
Feb-02-24	Downgrade	Bernstein	Outperform → Mkt Perform
Jan-31-24	Downgrade	Robert W. Baird	Neutral → Underperform	$325
Jan-31-24	Downgrade	Maxim Group	Buy → Hold

Show Previous Ratings

Jul-05-25 04:51AM	The Best Stocks to Invest $1,000 In Right Now (Motley Fool)
Jul-04-25 01:18PM	Vertex reports long-term results for Casgevy in sickle cell and thalassaemia (Clinical Trials Arena)
Jul-03-25 09:38AM	Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY (PR Newswire)
Jul-02-25 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
07:08AM	Loading…
07:08AM	Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold (Pharmaceutical Technology)
Jul-01-25 06:00PM	Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts (Zacks)
07:34AM	Vertex Announces European Commission Approval of ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis (Business Wire)
Jun-30-25 08:42AM	AbbVie to buy Capstan for up to $2.1 billion in immunology push (Reuters)
08:30AM	Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock? (Zacks)
06:20AM	Should You Invest in the VanEck Biotech ETF (BBH)? (Zacks)
Jun-29-25 12:53PM	H.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference Results (Insider Monkey)
Jun-27-25 09:19AM	Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug (Insider Monkey)
Jun-26-25 05:50PM	5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q1 Earnings Call (StockStory)
Jun-25-25 10:03AM	CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? (Zacks)
12:45PM	Loading…
Jun-24-25 12:45PM	Vertex Pharmaceuticals Presents "Unprecedented" Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit (Insider Monkey)
Jun-23-25 05:35AM	Vertex presents data from Phase I/II stage of trial for type 1 diabetes (Clinical Trials Arena)
04:00AM	Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea (Business Wire)
Jun-20-25 07:15PM	Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions (Business Wire)
06:00PM	Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market (Zacks)
Jun-19-25 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
04:25AM	2 Growth Stocks to Buy and Hold for 10 Years (Motley Fool)
Jun-16-25 07:04AM	3 Growth Stocks You Can Buy Right Now Without Any Hesitation (Motley Fool)
Jun-13-25 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Moves -1.00%: What You Should Know (Zacks)
Jun-11-25 07:35PM	Vertex Presents New Data on the Benefits of ALYFTREK (Insider Monkey)
10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-09-25 06:20AM	Should You Invest in the iShares Biotechnology ETF (IBB)? (Zacks)
Jun-06-25 04:08PM	Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? (MarketWatch)
12:00PM	Vertex Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference (Business Wire)
11:31AM	Loading…
11:31AM	Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? (Zacks)
Jun-05-25 11:30AM	Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-04-25 11:30AM	Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
09:00AM	Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know (Zacks)
Jun-02-25 07:00AM	3 No-Brainer Healthcare Stocks to Buy in June (Motley Fool)
04:10AM	4 Monster Stocks to Buy and Hold for the Next Decade (Motley Fool)
Jun-01-25 06:15AM	2 Top Stocks to Buy Right Now (Motley Fool)
May-28-25 11:27AM	Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer (Zacks)
05:15AM	3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow (Motley Fool)
May-26-25 04:46AM	3 Top Growth Stocks to Buy in the Second Half of 2025 (Motley Fool)
May-24-25 01:05PM	2 Monster Growth Stocks to Buy and Hold for 10 Years (Motley Fool)
May-23-25 04:17AM	VIRTUNE ACCELERATES EUROPEAN EXPANSION WITH XRP ETP DEBUT ON DEUTSCHE BORSE XETRA (GlobeNewswire)
May-21-25 04:48AM	Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 (Motley Fool)
May-20-25 11:50AM	CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies (Zacks)
03:43AM	CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy? (Motley Fool)
May-19-25 07:36AM	VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss (StockStory)
May-18-25 08:31PM	The Top Corporate Board Directors (The Wall Street Journal)
May-17-25 06:10PM	Warren Buffett Remains Optimistic About America. Here Are Top American Companies Worth Investing In. (Motley Fool)
May-15-25 04:05PM	Vertex to Participate in Upcoming Investor Conferences (Business Wire)
01:49PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
May-13-25 08:10AM	Best Biotech Stocks to Buy in 2025 (MarketBeat)
07:10AM	2 Biotech Stocks That Are Screaming Buys in May (Motley Fool)
04:52AM	This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next (Motley Fool)
May-12-25 07:08AM	Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years (Motley Fool)
May-11-25 04:55PM	Is Vertex Pharmaceuticals (VRTX) Among the Best Stocks to Buy According to Jim Simons' Renaissance Technologies? (Insider Monkey)
May-10-25 04:12AM	My Favorite Tariff Safe-Haven Stock to Buy on the Dip (Motley Fool)
May-09-25 10:03AM	Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment (Insider Monkey)
09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:30AM	4 No-Brainer Stocks to Buy Right Now (Motley Fool)
May-08-25 08:03AM	Viatris new form of old pain drug scores in large trials (BioPharma Dive)
May-07-25 04:03PM	Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course (Seeking Alpha)
03:30PM	Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss (Seeking Alpha)
12:16PM	S&P 500's five most overbought and oversold stocks (Seeking Alpha)
12:06PM	SA analyst upgrades: TSLA, MSFT, AMD, PLTR, VRTX, ONON, CB (Seeking Alpha)
07:40AM	CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks (Zacks)
07:26AM	VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations (Zacks)
04:49AM	Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip (Motley Fool)
12:31AM	1 S&P 500 Stock with Impressive Fundamentals and 2 to Ignore (StockStory)
May-06-25 07:52PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research) -10.03%
05:09PM	Stocks to Watch Recap: Palantir, Ford, Mattel, DoorDash (The Wall Street Journal)
04:49PM	S&P 500 Gains & Losses Today: Stocks Fall for Second Day as Palantir, Pharmaceuticals Drop (Investopedia)
04:39PM	Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks (Investor's Business Daily)
04:28PM	Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? (Benzinga)
04:25PM	Stock Market Today: Dow Jones, S&P 500 Fall Again; Gold Stocks Rally While Palantir Tumbles (Live Coverage) (Investor's Business Daily)
03:18PM	Jim Cramer on Vertex (VRTX): "Vertex's Painkiller Could Be Revolutionary" (Insider Monkey)
02:41PM	Stocks to Watch Tuesday: Palantir, Ford, Mattel, DoorDash (The Wall Street Journal)
02:08PM	Uber-Pony AI partnership, EVgo boost, Vertex earnings miss (Yahoo Finance Video)
12:31PM	Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Heres Why. (Barrons.com)
11:59AM	VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened (Zacks)
11:58AM	Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More (Investopedia)
10:48AM	Vertex Pharmaceuticals Stock Sinks as Costs Soar (Investopedia)
10:36AM	Why Vertex Pharmaceuticals Stock Is Sinking Today (Motley Fool)
09:11AM	Rising Costs Weigh on Vertex Q1 Earnings (Motley Fool)
07:29AM	Q1 2025 Vertex Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:06AM	Vertex Pharmaceuticals Inc (VRTX) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Challenges (GuruFocus.com)
May-05-25 08:01PM	Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:15PM	Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates (Zacks)
04:17PM	Vertex misses quarterly results on weaker-than-expected sales for cystic fibrosis drug (Reuters)
04:09PM	Vertex: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Vertex Reports First Quarter 2025 Financial Results (Business Wire)
07:00AM	Stock Market Selloff: 4 No-Brainer Stocks to Buy Right Now (Motley Fool)
06:45AM	3 No-Brainer Stocks to Buy in May (Motley Fool)
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-04-25 07:42AM	Wall Street Week Ahead (Seeking Alpha)
06:00AM	What To Expect in the Markets This Week (Investopedia)
04:42AM	5 Growth Stocks to Buy in May and Go Away (Motley Fool)
May-03-25 11:00AM	Ford, Disney, And AMD To Report Results Next Week (Seeking Alpha)
May-02-25 01:20PM	Viatris Q1 Earnings Release: What's in Store for the Stock? (Zacks)
May-01-25 09:35AM	ClearBridge Growth Portfolios Q1 2025 Commentary (Seeking Alpha)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LR 2019 Benefit Trust	Director	May 21 '25	Proposed Sale	447.18	170	76,021		May 21 04:58 PM
SR 2019 Benefit Trust	Director	May 21 '25	Proposed Sale	447.18	170	76,021		May 21 04:58 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	May 15 '25	Sale	424.69	52	22,084	23,281	May 19 05:07 PM
ALTSHULER DAVID	Officer	May 15 '25	Proposed Sale	424.69	52	22,084		May 15 10:36 AM
Bhatia Sangeeta N.	Director	May 02 '25	Sale	505.86	400	202,344	4,831	May 05 04:14 PM
Bhatia Sangeeta N.	Director	May 02 '25	Proposed Sale	505.86	400	202,344		May 02 09:47 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 13 '25	Sale	510.00	3,231	1,647,810	23,281	Mar 17 04:09 PM
ALTSHULER DAVID	Officer	Mar 13 '25	Proposed Sale	510.00	3,231	1,647,810		Mar 13 11:10 AM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Mar 10 '25	Sale	500.00	3,298	1,649,000	51,671	Mar 12 04:11 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 10 '25	Sale	499.99	3,242	1,620,968	51,239	Mar 12 04:10 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 10 '25	Sale	500.00	3,231	1,615,500	26,512	Mar 12 04:08 PM
Tatsis Ourania	Officer	Mar 10 '25	Proposed Sale	499.99	3,242	1,620,968		Mar 10 01:58 PM
WAGNER CHARLES F JR	Officer	Mar 10 '25	Proposed Sale	500.00	3,298	1,649,000		Mar 10 01:02 PM
ALTSHULER DAVID	Officer	Mar 10 '25	Proposed Sale	500.00	3,231	1,615,500		Mar 10 12:42 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 04 '25	Sale	485.49	4,058	1,970,118	54,481	Mar 06 04:08 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 03 '25	Sale	490.00	3,231	1,583,190	29,743	Mar 05 04:08 PM
Tatsis Ourania	Officer	Mar 04 '25	Proposed Sale	485.49	4,058	1,970,118		Mar 04 01:39 PM
ALTSHULER DAVID	Officer	Mar 03 '25	Proposed Sale	490.00	3,231	1,583,190		Mar 03 04:17 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 27 '25	Sale	475.34	530	251,930	58,539	Feb 28 04:48 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 27 '25	Sale	475.34	2,650	1,259,651	19,352	Feb 28 04:36 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 27 '25	Sale	480.00	1,272	610,560	32,974	Feb 28 04:23 PM
ALTSHULER DAVID	Officer	Feb 27 '25	Proposed Sale	480.00	1,272	610,560		Feb 27 11:20 AM
Atkinson Edward Morrow III	Officer	Feb 27 '25	Proposed Sale	475.34	2,650	1,259,651		Feb 27 10:18 AM
Tatsis Ourania	Officer	Feb 27 '25	Proposed Sale	475.34	530	251,930		Feb 27 10:14 AM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 25 '25	Sale	480.95	354	170,256	64,031	Feb 26 04:15 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 25 '25	Sale	480.95	1,767	849,839	24,484	Feb 26 04:09 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 25 '25	Sale	480.95	884	425,160	9,086	Feb 26 04:06 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 25 '25	Sale	480.95	848	407,846	40,200	Feb 26 04:04 PM
Tatsis Ourania	Officer	Feb 25 '25	Proposed Sale	480.95	354	170,256		Feb 25 11:38 AM
ALTSHULER DAVID	Officer	Feb 25 '25	Proposed Sale	480.95	848	407,846		Feb 25 11:13 AM
Atkinson Edward Morrow III	Officer	Feb 25 '25	Proposed Sale	480.95	1,767	849,839		Feb 25 10:59 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 20 '25	Sale	480.00	1,111	533,280	45,019	Feb 24 04:07 PM
ALTSHULER DAVID	Officer	Feb 20 '25	Proposed Sale	480.00	1,111	533,280		Feb 20 03:45 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 18 '25	Sale	455.06	244	111,035	67,695	Feb 19 04:36 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 18 '25	Sale	455.06	1,657	754,034	17,606	Feb 19 04:28 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 18 '25	Sale	455.06	671	305,345	10,798	Feb 19 04:21 PM
Tatsis Ourania	Officer	Feb 18 '25	Proposed Sale	455.06	244	111,035		Feb 18 11:34 AM
Biller Jonathan	Officer	Feb 18 '25	Proposed Sale	455.06	1,657	754,034		Feb 18 11:29 AM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 11 '25	Sale	459.83	310	142,547	64,021	Feb 12 04:50 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 11 '25	Sale	459.87	3,433	1,578,734	16,330	Feb 12 04:36 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 11 '25	Sale	459.83	1,747	803,323	23,225	Feb 12 04:29 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 11 '25	Sale	459.83	1,376	632,726	9,953	Feb 12 04:24 PM
Biller Jonathan	Officer	Feb 11 '25	Proposed Sale	459.87	3,433	1,578,744		Feb 11 11:57 AM
Tatsis Ourania	Officer	Feb 11 '25	Proposed Sale	459.83	310	142,547		Feb 11 11:05 AM
Atkinson Edward Morrow III	Officer	Feb 11 '25	Proposed Sale	459.83	1,747	803,323		Feb 11 09:49 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Nov 15 '24	Sale	478.56	15	7,178	25,813	Nov 19 04:08 PM
ALTSHULER DAVID	Officer	Nov 15 '24	Proposed Sale	478.56	15	7,178		Nov 15 10:31 AM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Nov 11 '24	Sale	518.27	3,000	1,554,810	44,137	Nov 13 04:15 PM
Kewalramani Reshma	CEO & President	Nov 08 '24	Sale	515.00	15,198	7,826,970	75,772	Nov 12 04:08 PM
Kewalramani Reshma	Officer	Nov 08 '24	Proposed Sale	515.00	15,198	7,826,970		Nov 08 02:58 PM
Biller Jonathan	EVP and Chief Legal Officer	Oct 02 '24	Sale	461.66	999	461,198	16,651	Oct 03 04:12 PM
Biller Jonathan	Officer	Oct 02 '24	Proposed Sale	461.66	999	461,198		Oct 02 10:04 AM
LEIDEN JEFFREY M	Executive Chairman	Aug 30 '24	Sale	499.00	3,784	1,888,216	9,994	Sep 04 04:13 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Option Exercise	152.74	646	98,670	5,081	Sep 04 04:12 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Sale	500.00	646	323,000	4,435	Sep 04 04:12 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Proposed Sale	500.00	646	323,000		Aug 30 04:47 PM
JEFFREY LEIDEN	Director	Aug 30 '24	Proposed Sale	493.35	3,784	1,866,836		Aug 30 04:23 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Option Exercise	152.74	1,292	197,340	5,727	Aug 12 04:08 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Sale	466.29	1,292	602,447	4,435	Aug 12 04:08 PM
Bozic Carmen	EVP and CMO	Aug 07 '24	Sale	476.75	2,280	1,086,990	23,259	Aug 08 04:06 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Proposed Sale	466.29	1,292	602,447		Aug 08 11:47 AM
Bozic Carmen	Officer	Aug 07 '24	Proposed Sale	476.75	2,280	1,086,990		Aug 07 09:52 AM
SACHS BRUCE I	Director	Aug 01 '24	Option Exercise	125.71	5,295	665,634	45,295	Aug 02 04:10 PM
SACHS BRUCE I	Director	Aug 01 '24	Sale	508.00	5,295	2,689,860	40,000	Aug 02 04:10 PM
Kewalramani Reshma	CEO & President	Jul 30 '24	Sale	505.00	15,202	7,677,010	90,970	Aug 01 04:17 PM
SACHS BRUCE I	Director	Aug 01 '24	Proposed Sale	508.00	5,295	2,689,860		Aug 01 03:34 PM
Kewalramani Reshma	Officer	Jul 30 '24	Proposed Sale	505.00	15,202	7,677,010		Jul 30 03:25 PM
Bozic Carmen	EVP and CMO	Jul 24 '24	Sale	488.46	2,280	1,113,689	25,539	Jul 25 04:06 PM
Kewalramani Reshma	CEO & President	Jul 22 '24	Sale	497.00	15,202	7,555,394	106,172	Jul 24 04:05 PM
Bozic Carmen	EVP and CMO	Jul 10 '24	Sale	487.34	2,280	1,111,135	27,819	Jul 12 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRTX

Vertex Pharmaceuticals, Inc

Upgrade your FINVIZ experience